Published in Bioengineering (Basel) on May 08, 2017
CHARACTERISTICS OF AN IMMUNE SYSTEM COMMON TO CERTAIN EXTERNAL SECRETIONS. J Exp Med (1965) 8.32
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med (2008) 6.82
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28
Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol (2007) 4.96
Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev (2006) 4.02
Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov (2009) 3.66
Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med (2002) 3.12
The structure and function of human IgA. Biochem J (1990) 2.65
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A (2011) 2.65
Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol (1999) 2.44
GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res (2012) 2.41
The function of immunoglobulin A in immunity. J Pathol (2006) 2.31
Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins. Nature (1984) 2.16
The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions. J Biol Chem (1998) 2.10
IgA and the IgA Fc receptor. Trends Immunol (2001) 2.05
IgA Fc receptors. Annu Rev Immunol (2001) 1.98
Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res (1999) 1.93
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood (2011) 1.91
Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol (2004) 1.91
Biopharmaceutical benchmarks 2014. Nat Biotechnol (2014) 1.87
A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol (2010) 1.84
Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol (1995) 1.74
Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem (2003) 1.68
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther (2013) 1.60
Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Nature (2003) 1.53
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood (2013) 1.34
Biomarkers for personalized oncology: recent advances and future challenges. Metabolism (2014) 1.29
Underglycosylation of IgA1 hinge plays a certain role for its glomerular deposition in IgA nephropathy. J Am Soc Nephrol (1999) 1.26
Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized "inhibisome" clusters. Sci Signal (2011) 1.19
Structure and function relationships in IgA. Mucosal Immunol (2011) 1.18
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol (2014) 1.13
Heterogeneity of O-glycosylation in the hinge region of human IgA1. Mol Immunol (2000) 1.11
Bivalent binding of IgA1 to FcalphaRI suggests a mechanism for cytokine activation of IgA phagocytosis. J Mol Biol (2003) 1.11
A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol (2011) 1.07
Purification and characterization of chimeric human IgA1 and IgA2 expressed in COS and Chinese hamster ovary cells. J Immunol (1993) 1.07
The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. J Exp Med (2000) 1.06
Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. J Am Soc Nephrol (1999) 1.06
Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies. J Immunol (2012) 1.04
Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18). Blood (1999) 1.03
Antibody-drug conjugates: present and future. MAbs (2014) 1.02
The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol (2011) 1.01
Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol (2005) 1.01
Analysis of IgA1 N-glycosylation and its contribution to FcalphaRI binding. Biochemistry (2008) 1.00
Structural analysis of the N-glycans from human immunoglobulin A1: comparison of normal human serum immunoglobulin A1 with that isolated from patients with rheumatoid arthritis. Biochem J (1994) 1.00
Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum Antibodies Hybridomas (1994) 0.98
Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol (2000) 0.98
Recombinant human IgA expressed in insect cells. Proc Natl Acad Sci U S A (1994) 0.97
Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol (2007) 0.96
Evidence for involvement of IgA1 hinge glycopeptide in the IgA1-IgA1 interaction in IgA nephropathy. J Am Soc Nephrol (1997) 0.95
Differential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inflammation in IgA nephropathy. J Am Soc Nephrol (2006) 0.94
Amplified gene location in chromosomal DNA affected recombinant protein production and stability of amplified genes. Biotechnol Prog (2000) 0.94
Divergence of human alpha-chain constant region gene sequences. A novel recombinant alpha 2 gene. J Immunol (1994) 0.93
FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood (1997) 0.93
Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood. J Immunol (1998) 0.93
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood (2002) 0.92
Mutagenesis of the human IgA1 heavy chain tailpiece that prevents dimer assembly. J Immunol (1996) 0.91
IgA function--variations on a theme. Immunology (2004) 0.91
Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol (2011) 0.90
Characterization of monoclonal immunoglobulin a and g against shiga toxin binding subunits produced by intranasal immunization. Scand J Immunol (2008) 0.90
Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res (1999) 0.89
Monitoring recombinant human interferon-gamma N-glycosylation during perfused fluidized-bed and stirred-tank batch culture of CHO cells. Biotechnol Bioeng (1998) 0.89
A human immunoglobulin (Ig)A calpha3 domain motif directs polymeric Ig receptor-mediated secretion. J Exp Med (1999) 0.89
Anti-inflammatory role of the IgA Fc receptor (CD89): from autoimmunity to therapeutic perspectives. Autoimmun Rev (2012) 0.88
IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med (2013) 0.88
Primary breast cancer tumours contain high amounts of IgA1 immunoglobulin: an immunohistochemical analysis of a possible carrier of the tumour-associated Tn antigen. PLoS One (2013) 0.87
Serum-free production and purification of chimeric IgA antibodies. J Immunol Methods (2009) 0.87
Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity. PLoS One (2014) 0.87
Production of secretory IgA antibodies in plants. Biomol Eng (2001) 0.86
The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP1 19). BMC Biotechnol (2011) 0.86
Combinatorial Analysis of Secretory Immunoglobulin A (sIgA) Expression in Plants. Int J Mol Sci (2013) 0.86
Glycoform composition profiling of O-glycopeptides derived from human serum IgA1 by matrix-assisted laser desorption ionization-time of flight-mass spectrometry. Anal Biochem (2004) 0.86
Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. Biotechnol J (2014) 0.86
Differences in N-glycan structures found on recombinant IgA1 and IgA2 produced in murine myeloma and CHO cell lines. MAbs (2010) 0.85
Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. Contemp Oncol (Pozn) (2013) 0.85
Antibody- and Fc-receptor-based therapeutics for malaria. Clin Sci (Lond) (2006) 0.85
Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J Biol Chem (2012) 0.85
Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy. J Immunol (2011) 0.84
Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Cancer Res (2001) 0.83
Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody. MAbs (2014) 0.82
Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89). Cancer Res (2001) 0.82
Recombinant IgA production: single step affinity purification using camelid ligands and product characterization. J Immunol Methods (2012) 0.82
Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein. J Clin Immunol (2012) 0.82
Repeated integration of antibody genes into a pre-selected chromosomal locus of CHO cells using an accumulative site-specific gene integration system. Cytotechnology (2011) 0.81
How ITAMs inhibit signaling. Sci Signal (2011) 0.81
Glycosylation of immunoglobulin A influences its receptor binding. Scand J Immunol (1999) 0.81
Effect of production method and gene amplification on the glycosylation pattern of a secreted reporter protein in CHO cells. Biotechnol Prog (2005) 0.80
Incomplete assembly of IgA2m(2) in Chinese hamster ovary cells. Mol Immunol (2007) 0.79
A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA. MAbs (2015) 0.78
Therapy: This time it's personal. Nature (2014) 0.78
Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. Haematologica (2012) 0.78
Simplifying the synthesis of SIgA: combination of dIgA and rhSC using affinity chromatography. Methods (2013) 0.78
Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages. J Immunol (2000) 0.78
An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo. Cancer Res (2015) 0.78
Limited role of charge matching in the interaction of human immunoglobulin A with the immunoglobulin A Fc receptor (Fc alpha RI) CD89. Immunology (2003) 0.76
Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting. MAbs (2015) 0.75